Literature DB >> 20087968

Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus.

Josephine Simonetti1, Lisa Bulkow, Brian J McMahon, Chriss Homan, Mary Snowball, Susan Negus, James Williams, Stephen E Livingston.   

Abstract

UNLABELLED: Some individuals who are chronically infected with hepatitis B virus (HBV) eventually lose hepatitis B surface antigen (HBsAg). Hepatocellular carcinoma (HCC) has been demonstrated to occur in a few patients after loss of HBsAg. Neither factors associated with loss of HBsAg nor the incidence of HCC thereafter have been clearly elucidated. We performed a prospective population-based cohort study in 1,271 Alaska Native persons with chronic HBV infection followed for an average of 19.6 years to determine factors associated with loss of HBsAg and risk of developing HCC thereafter. HBsAg loss occurred in 158 persons for a rate of HBsAg clearance of 0.7%/year. Older age, but not sex, was associated with clearance of HBsAg, and loss of HBsAg was not associated with any particular HBV genotypes (A, B, C, D, and F) found in this population. Participants were followed for an average of 108.9 months after HBsAg loss. Six patients, two with cirrhosis and four without, developed HCC a mean of 7.3 years after HBsAg clearance (range, 2.0-15.5 years). The incidence of HCC after clearance of HBsAg was 36.8 per 100,000 per year (95% CI 13.5-80.0) which was significantly lower than the rate in those who remained HBsAg-positive (195.7 cases per 100,000 person-years of follow-up [95% CI 141.1-264.5; P < 0.001]). After loss of HBsAg, HBV DNA was detected in the sera of 28 (18%) of those who cleared a median of 3.6 years after clearance.
CONCLUSION: HCC can occur in persons with chronic hepatitis B who have lost HBsAg, even in the absence of cirrhosis. These persons should still be followed with periodic liver ultrasound to detect HCC early.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20087968     DOI: 10.1002/hep.23464

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  61 in total

1.  Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B-Alaska, 2001-2010.

Authors:  Rania A Tohme; Lisa Bulkow; Chriss E Homan; Susan Negus; Brian J McMahon
Journal:  J Clin Virol       Date:  2013-08-16       Impact factor: 3.168

2.  HBV reactivation risk factors in patients with chronic HBV infection with low replicative state and resolved HBV infection undergoing hematopoietic stem cell transplantation in Korea.

Authors:  Chung Hwan Jun; Ban Suk Kim; Chan Young Oak; Du Hyeon Lee; Eunae Cho; Sung Bum Cho; Sung Kyu Choi; Chang Hwan Park; Young Eun Joo; Je-Jung Lee; Hyeoung-Joon Kim
Journal:  Hepatol Int       Date:  2016-06-28       Impact factor: 6.047

Review 3.  Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs.

Authors:  Francesca De Nard; Monica Todoerti; Vittorio Grosso; Sara Monti; Silvia Breda; Silvia Rossi; Carlomaurizio Montecucco; Roberto Caporali
Journal:  World J Hepatol       Date:  2015-03-27

4.  Changes in the serum level of hepatitis B virus (HBV) surface antigen over the natural course of HBV infection.

Authors:  Akihiro Matsumoto; Eiji Tanaka; Susumu Morita; Kaname Yoshizawa; Takeji Umemura; Satoru Joshita
Journal:  J Gastroenterol       Date:  2012-02-29       Impact factor: 7.527

Review 5.  KASL clinical practice guidelines: management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

6.  HBsAg loss in chronic hepatitis B: pointers to the benefits of curative therapy.

Authors:  Geoffrey Dusheiko; Bo Wang; Ivana Carey
Journal:  Hepatol Int       Date:  2016-05-31       Impact factor: 6.047

7.  Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China.

Authors:  Yao Hu; Ying-Zi Ye; Li-Jing Ye; Xiao-Hong Wang; Hui Yu
Journal:  World J Pediatr       Date:  2019-09-05       Impact factor: 2.764

8.  HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long-term outcomes.

Authors:  Tien Huey Lim; Edward Gane; Chris Moyes; Barry Borman; Chris Cunningham
Journal:  Hepatol Int       Date:  2016-03-08       Impact factor: 6.047

9.  Quantitative Levels of Hepatitis B Virus DNA and Surface Antigen and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Receiving Long-Term Nucleos(t)ide Analogue Therapy.

Authors:  Miwa Kawanaka; Ken Nishino; Jun Nakamura; Takahito Oka; Noriyo Urata; Daisuke Goto; Mitsuhiko Suehiro; Hirofumi Kawamoto; Masatoshi Kudo; Gotaro Yamada
Journal:  Liver Cancer       Date:  2014-03       Impact factor: 11.740

Review 10.  Screening and diagnosis of HBV in low-income and middle-income countries.

Authors:  Jean-Pierre Allain; Ohene Opare-Sem
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-14       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.